Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.

ABSTRACT: The tumor necrosis factor (TNF) antagonist infliximab was previously found to reduce depressive symptoms in patients with treatment-resistant major depression (TRD) who exhibited high baseline inflammation, as reflected by plasma C-reactive protein (CRP) >5 mg/L. Further predictors of antidepressant response to infliximab included differential expression of peripheral blood gene transcripts that were related not only to inflammation but also to glucose and lipid metabolism. To determine whether plasma biomarkers of glucose and lipid metabolism were similarly associated with antidepressant response to infliximab and with relevant gene transcripts, we measured concentrations of glucose, insulin, and protein hormones that regulate glucose homeostasis and metabolism (leptin, resistin, and adip

SUBMITTER: Bekhbat M 

PROVIDER: S-EPMC6214671 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature